TITLE

Decoding Autism

AUTHOR(S)
LANGRETH, ROBERT
PUB. DATE
December 2010
SOURCE
Forbes Asia;Dec2010, Vol. 6 Issue 14, p114
SOURCE TYPE
Periodical
DOC. TYPE
Article
ABSTRACT
The article offers information on the research work of neuroscientist Mark Bear regarding the treatment of some forms of autism and mental retardation with the drugs available in the medicine field. It mentions that an inherited disease called fragile X syndrome which causes autism can be treated by anxiety drugs called mGluR5 inhibitors from Seaside Therapeutics LLC. Bear also reports that protein production problems are connected with many cases of autism.
ACCESSION #
56872052

 

Related Articles

  • Seaside Therapeutics Blazes a Trail in Fragile X. Shaffer, Catherine // BioWorld Today;6/3/2011, Vol. 22 Issue 107, p1 

    The article reports on the Phase III trial of Seaside Therapeutics Inc. of a possible drug to treat core symptoms of Fragile X syndrome. It discusses the function of the drug compound STX209 in moderating the gamma-amino butyric acid type B (GABA-B) receptor in autism and disorders of brain...

  • Seaside Therapeutics raises $30 million in financing.  // PharmaWatch: CNS;Nov2009, Vol. 8 Issue 11, p13 

    The article reports on the 30 million dollars raised by Seaside Therapeutics, a private investment firm institutionalized in the research of autism and fragile x syndrome. The fund will be spent to improve therapeutic nominees suffering from such condition. According to the president and chief...

  • Seaside Therapeutics Wants Robust Effects On Fragile X. Breindl, Anette // BioWorld Today;12/26/2007, Vol. 18 Issue 248, p1 

    The article reports on the lead program of Seaside Therapeutics that focuses on the treatment of Fragile X syndrome. According to company Chief Executive Officer (CEO) Randy Carpenter, their aim is to come up with treatments for autism spectrum disorders. Under the program, the company will make...

  • Seaside Therapeutics Publishes Review of Advances in the Treatment of Fragile X Syndrome in American Chemical Society Chemical Neuroscience.  // Biomedical Market Newsletter;5/17/2011, p331 

    The article reports on the publication by Seaside Therapeutics LLC of a review paper discussing the evolving drug and scientific development field for fragile X syndrome (FXS). It states that the review article obtained information from over 100 researches to recommend a paradigm modification in...

  • Seaside Therapeutics Initiates Pivotal Phase 3 Study of STX209 in Fragile X Syndrome.  // Biomedical Market Newsletter;6/9/2011, p968 

    The article focuses on the pivotal Phase 3 study initiated by Seaside Therapeutics Inc. for the evaluation of STX209 drug on social impairment among adults and adolescents with fragile X syndrome. Randall L. Carpenter of Seaside Therapeutics Inc. says that STX209 might be able to improve the...

  • Seaside Raises $30M Series B for Autism Work.  // Bioworld Week;9/21/2009, Vol. 17 Issue 38, p5 

    The article reports on the 30 million dollars Series B raised by Seaside Therapeutics LLC for the funding of its activities on autism in Cambridge, Massachusetts. It states that Seaside has raised the money from a private family investment firm to fund its work on autism. It adds that...

  • From FMRP Function to Potential Therapies for Fragile X Syndrome. Sethna, Ferzin; Moon, Changjong; Wang, Hongbing // Neurochemical Research;Jun2014, Vol. 39 Issue 6, p1016 

    Fragile X syndrome (FXS) is caused by mutations in the fragile X mental retardation 1 ( FMR1) gene. Most FXS cases occur due to the expansion of the CGG trinucleotide repeats in the 5′ un-translated region of FMR1, which leads to hypermethylation and in turn silences the expression of FMRP...

  • Obsessive-Compulsive Disorder and Hyperphagia in a Boy with Fragile X Syndrome: A Case Report. Mostafavi, Seyed-Ali; Yazdian-Anari, Pouria; Mahmoudi, Maryam; Mirzaei, Fahimeh; Bidaki, Reza; Mahmoodi Meymand, Mohammad Hossein // Iranian Journal of Diabetes & Obesity (IJDO);Winter2014, Vol. 6 Issue 4, p182 

    Objective: Fragile X syndrome is the second etiology for inherited mental retardation. It may concomitant with other psychiatric disorders. Intellectual disability (ID) is a state of functioning that typically begins in childhood and is characterized by limitations in intelligence and adaptive...

  • Drug could get into the autistic mind. Biever, Celeste // New Scientist;5/29/2010, Vol. 206 Issue 2762, p12 

    The article discusses the development of drugs for individuals with autism to improve their social skills. According to the author, drugs are being tested that may help people learn more, speak better, and gain social skills so they can communicate better. Topics include an overview of a...

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics